To test whether the experimental drug GDC-0449 is safe and effective for advanced basal cell carcinoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-004945-27

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is - to estimate the clinical benefit of Vismodegib given as therapy for patients with locally advanced or metastatic BCC, as measured by overall response rate (ORR).


Critère d'inclusion

  • • metastatic BCC with histologic confirmation of a distant BCC metastasis (e.g., lung, liver, lymph nodes, or bone)
  • • locally advanced BCC considered inoperable or with medical contraindication to surgery
  • • nevoid BCC syndrome (Gorlin syndrome), meeting the criteria for locally advanced or metastatic disease